FSD Pharma Inc. (NASDAQ:HUGE – Get Rating) was the target of a significant increase in short interest in the month of February. As of February 28th, there was short interest totalling 456,800 shares, an increase of 37.4% from the February 13th total of 332,500 shares. Currently, 2.8% of the shares of the company are short sold. Based on an average trading volume of 149,200 shares, the days-to-cover ratio is presently 3.1 days.
FSD Pharma Price Performance
NASDAQ HUGE opened at $1.41 on Tuesday. FSD Pharma has a 52-week low of $0.62 and a 52-week high of $1.88. The firm has a 50-day moving average price of $1.27 and a 200 day moving average price of $1.00.
Get FSD Pharma alerts:Institutional Inflows and Outflows
A hedge fund recently raised its stake in FSD Pharma stock. Susquehanna International Group LLP lifted its stake in FSD Pharma Inc. (NASDAQ:HUGE – Get Rating) by 141.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 53,190 shares of the company's stock after purchasing an additional 31,200 shares during the period. Susquehanna International Group LLP owned approximately 0.14% of FSD Pharma worth $42,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 1.64% of the company's stock.
About FSD Pharma
(Get Rating)
FSD Pharma, Inc is a specialty biotech pharmaceutical research and development company. It focuses on developing over time a robust pipeline of FDA-approved synthetic compounds targeting the end cannabinoid system of the human body to treat certain diseases of the central nervous system and autoimmune disorders of the skin, GI tract, and the musculoskeletal system.
Read More
- Get a free copy of the StockNews.com research report on FSD Pharma (HUGE)
- Is Academy Sports And Outdoors A Buy For 2023?
- Regional Bank Depositors Turn to Bank of America After SVB Fail
- DocGo: A Growth Stock Going Higher In 2023
- Are There Opportunities In The Silicon Valley Bank Collapse?
- Bonds are a Safe Haven Again, Still Time to Buy?
Receive News & Ratings for FSD Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FSD Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
